Evidence map›Paper›PMID 42907634›Full record

ReviewAdvances in experimental medicine and biology2026

Investigation of Antibody-Drug Conjugates by Mass Spectrometry.

Aneeta Arshad, Rylie Flack, Isadora Barbosa Freire, Costel C Darie, Madhuri Jayathirtha

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aneeta ArshadBiochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, USA.
Rylie FlackBiochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, USA.
Isadora Barbosa FreireBiochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, USA.
Costel C DarieBiochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, USA.
Madhuri JayathirthaBiochemistry and Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, USA. jayathm@clarkson.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ADCs are empowered monoclonal antibodies that are designed to harness their targeting ability by linking them to cell-killing agents. They are made up of three main components: the antibody, linker, and the cytotoxic drug. The specificity of the antibody with the antigen on the tumor cell surface helps with its internalization into the cell, after which the active drug is released, causing cell death. The investigation of ADCs can be done using a variety of MS methods. Here, we talk about the bottom-up approach, the top-down approaches such as ECD and ETD, the ESI/MS method, and IM-MS. Further, we also focus on the applications of MALDI/MS such as UV-MALDI, IR-MALDI and IMS-MALDI and provide examples of the mass spectra that provide a tremendous amount of information on ADC structures.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsImmunoconjugatesMass SpectrometryAnimalsHumansSpectrometry, Mass, Electrospray IonizationSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntibodies, MonoclonalAntineoplastic AgentsImmunoconjugatesAntibody drug conjugatesMass spectrometryProtein characterizationTherapeutics

Identifiers

PMID42907634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.